Autism Translation to Treatments Project

Print Article Download PDF

Summary

  • Study director: Robert Hendren, DO
  • Sponsor: Private Foundation: Jane Johnson Foundation
  • Recruiting?: Yes
  • Official study title: Autism Translation to Treatments (AT3) Project
  • Conditions studied: Autistic disorder
  • Purpose: The AT3 Study is a novel prospective study which will carefully monitor young children who were recently diagnosed with autism and who are undergoing detailed biomedical evaluation and treatment with their regular physician at one of five study sites in the United States. The overarching goal of the project is to develop an integrated, comprehensive, science-based, assessment of biomedical mechanisms involved in the etiology of autism, which will be critical to track and evaluate the efficacy of targeted treatments for autism and related neurodevelopmental disorders.

Eligibility

  • Inclusion criteria:
    • Age 2–8 years old
    • DSM-IV-TR or DSM-V criteria for autism on the basis of clinical evaluation
    • Rated by examining clinician as at least "moderate" on the CGI-Severity scale (a rating of ≥4)
    • Willing to complete study questionnaires
    • o Regular access to the internet, which will be used to complete study questionnaires
  • Exclusion criteria:
    • Primary diagnosis of bipolar disorder, schizophrenia, or psychosis
    • IQ less than 40
    • Metabolic disturbance or any severe unstable medical illness
    • Inability of parents or caretakers to give informed consent, travel to the visits, administer treatments, or arrange for completion of rating scales

What is involved?

  • Testing: Online parent questionnaires
  • Frequency of visits: Every 3 months
  • Materials needed prior to evaluation: Access to the internet
  • Costs: None

Contact information